RxDoctor Payments Data

Peter Segall, MD

Cardiovascular Disease · Miami Beach, FLNPI 1326079864

Payments from drug & device makers

$377in general payments, 2019–2025

Across 19 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$101
  • Amgen$73
  • Exact Sciences$41
  • Lilly USA, LLC$36
  • Baxter Healthcare$22
  • Heartflow, Inc.$19
  • plus $84 from 5 others

What the payments were for

  • Food & beverage$377100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$377 in reported general payments places this provider in the 15th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$176,685
Medicare patients
321
Services billed
3,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban144$138,221
MounjaroTirzepatide83$96,441
Repatha SureclickEvolocumab60$55,309
XareltoRivaroxaban21$31,877
JanuviaSitagliptin Phosphate39$29,932
JanumetSitagliptin Phos/Metformin Hcl21$25,256
MyrbetriqMirabegron16$19,235
FarxigaDapagliflozin Propanediol28$19,209
MultaqDronedarone Hcl12$16,627
JardianceEmpagliflozin13$15,962
GemtesaVibegron11$13,748
LivaloPitavastatin Calcium11$10,526
Dexlansoprazole DrDexlansoprazole27$10,245
LinzessLinaclotide16$9,499
BrilintaTicagrelor15$8,964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$18$141,080165 claims
Lilly USA, LLCMounjaro$36$96,44183 claims
Johnson & JohnsonXarelto$18$31,87721 claims
Sanofi-aventis U.S. LLCMultaq$19$16,62712 claims
Kowa Pharmaceuticals America, Inc.Livalo$12$10,52611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →